SCHEDULE 13G/A: Armistice Capital and Steven Boyd Disclose 4.99% Passive Stake in Aligos Therapeutics
Beneficial Ownership Report
Armistice Capital, LLC and Steven Boyd have filed an amended Schedule 13G, reporting a passive beneficial ownership of 4.99% in Aligos Therapeutics, Inc. as of December 31, 2024.
Summary
- Armistice Capital, LLC and Steven Boyd, collectively referred to as the 'Reporting Persons', have filed an Amendment No. 2 to Schedule 13G regarding their beneficial ownership in Aligos Therapeutics, Inc.
- As of December 31, 2024, the Reporting Persons collectively beneficially own 188,438 shares of Aligos Therapeutics, Inc. Common Stock.
- This ownership represents 4.99% of the outstanding Common Stock of Aligos Therapeutics, Inc.
- Armistice Capital, LLC, as the investment manager, and Steven Boyd, as its managing member, exercise shared voting and dispositive power over these shares.
- The filing certifies that the securities were acquired and are held in the ordinary course of business and not for the purpose or with the effect of changing or influencing the control of the issuer.
Sentiment
Score: 5
Explanation: The document is a factual, routine regulatory disclosure of beneficial ownership and does not contain information that inherently indicates positive or negative sentiment regarding the company's performance or outlook.
Risks
- The filing indicates a passive investment, meaning the reporting persons do not intend to influence or change control of the issuer, which could limit potential activist engagement that might otherwise drive value.
Future Outlook
NA
Industry Context
This filing is a routine disclosure of a passive investment stake by an investment firm in a biotechnology company. It does not provide specific insights into Aligos Therapeutics' operational performance or the broader biotechnology industry trends, beyond indicating continued investment interest from a financial entity.
Stakeholder Impact
- Shareholders: Provides transparency regarding a significant, albeit passive, ownership stake by an investment firm, which can be a signal of institutional interest in the company's stock.
Key Dates
| Date | Description |
|---|---|
| 12/31/2024 | Date of event which requires the filing of this statement, reflecting the beneficial ownership position. |
| 02/14/2025 | Date the Schedule 13G/A Amendment No. 2 was signed and filed. |
Keywords
Aligos Therapeutics, Armistice Capital, Steven Boyd, Schedule 13G, Beneficial Ownership, Common Stock, Passive Investment, SEC Filing, Biotechnology, Pharmaceuticals
Disclaimer:The information provided here is for general informational purposes only and does not constitute financial advice, recommendation, or endorsement of any kind. It may contain errors or omissions. You should not rely on this information to make financial decisions. Always seek the advice of a qualified financial professional before making any investment or financial decisions. Use of this information is at your own risk.